Your Partner of Choice for Carbohydrates.

New Zealand Pharmaceuticals assigns to Altamira Bio

NZPlogoDextra's partner, New Zealand Pharmaceuticals assigns to Altamira Bio its assets related to the development of N-acetyl-D-mannosamine (ManNAc) for the treatment of the rare genetic disorder, GNE myopathy, and various kidney diseases.

 

Palmerston North – July 17, 2015 – Dextra's partner, New Zealand Pharmaceuticals Ltd (NZP) has transferred its Patent License and related Agreements with the U.S. National Institutes of Health (NIH) for the development of oral N-acetyl-D-mannosamine (DEX-M74, ManNAc) to U.S.-based Altamira Bio, Inc., a subsidiary of Fortress Biotech, Inc. (NASDAQ: FBIO).  NZP will receive milestone payments and royalties from Altamira Bio as the development program for DEX-M74 evolves.

 

ManNAc is a key compound in the sialic acid biosynthetic pathway and has the potential to treat a group of pathologies associated with hyposialylation of tissues including GNE myopathy, formerly known as Hereditary Inclusion Body Myopathy (HIBM) and various nephropathies.

 

NZP, which manufactures the DEX-M74 grade of ManNAc will remain the exclusive global supplier of DEX-M74 ManNAc to Altamira Bio.

NZP collaborated with researchers from the NIH’s National Center for Advancing Translational Sciences and National Human Genome Research Institute to preclinically develop DEX-M74. DEX-M74 is now being evaluated as a treatment for GNE myopathy in a phase II clinical trial at NIH.

 

“NZP is very pleased that the further development of DEX-M74 as a potential therapy for GNE myopathy and other diseases of hyposialylation will be undertaken by Altamira Bio. We are confident that Altamira has the capabilities and experience to rapidly develop DEX-M74 to provide solutions to treat sialylation disorders with unmet medical needs,” said Mr. Andy Lewis, CEO of NZP. “GNE myopathy is a severe debilitating muscle wasting disease and we are very grateful for the ongoing work conducted by the NIH scientists and physicians. This team has produced very compelling data on how ManNAc administration could supplement the genetic insufficiency to help these patients normalise their protein and complex lipid sialylation and retain their muscle strength. We are also encouraged by recent discoveries indicating the probable involvement of hyposialylation in kidney diseases and we are very pleased that Altamira and the NIH team will soon be testing DEX-M74 in patients with nephropathies in anticipation of maintaining or improving their kidney function.”

 

Destum Partners, Inc., acted as NZP’s transaction advisor, throughout the process.

 

Contact: Selwyn Yorke Ph.D.

Business Development Manager

Current News

Jul 11, 2017

Royal Society of Chemistry Carbohydrate Award 2017

Congratulations to Dr M. Carmen Galan as the recipient of the 2017 Royal Society of…
Feb 18, 2017

Labelled Glycans

Dextra are pleased to offer a range of N-glycans isotopically labelled with 13C, for use…
Oct 28, 2016

RSC Carbohydrate Meeting

Dextra will be attending the RSC Carbohydrate Group 50th Anniversary Conference at the…
GlycanArrayKit
Aug 10, 2016

Glycan Arrays

Dextra and the Institute for Glycomics at Griffith University have partnered to launch…
Jun 17, 2016

ICS 2016

Dextra will be attending ICS 2016, the XXVIII International Carbohydrate Symposium in New…
Jun 16, 2016

Dextra will be at CPhI China

We are pleased to announce that Dextra and New Zealand Pharmaceuticals Ltd will attend…
Apr 01, 2016

Glycobiotechnology 2016

Dextra will be attending the Glycobiotechnology 2016 meeting in Manchester on the 4th and…
Mar 11, 2016

PEGS Boston

We are pleased to announce that NZP and Dextra Laboratories will attend PEGS Boston,…
Feb 25, 2016

Heparinases

We are now offering a range of three heparinase enzymes that degrade glycosaminoglycans.…
Sep 15, 2015

CPhI Worldwide 2015

We are pleased to announce that NZP and Dextra Laboratories will attend CPhI Worldwide…
BG149
Sep 15, 2015

Fluorinated monosaccharides

We are excited to present our new range of fluorinated monosaccharides. The introduction…
blood-b-thumb
Sep 15, 2015

AFFINIDEX Columns

The AFFINDEXTM columns comprise our HAEMODEXTM A and B trisaccharides linked to Sepharose…
NZPlogo
Jul 20, 2015

New Zealand Pharmaceuticals assigns to Altamira Bio

Dextra's partner, New Zealand Pharmaceuticals assigns to Altamira Bio its assets related…
BM84
Jun 04, 2015

Bioprocessing Summit

We are pleased to announce that NZP-Dextra will attend The Bioprocessing Summit, on…
Jun 03, 2015

NZP-Dextra will be at The Bioprocessing Summit

We are pleased to announce that NZP-Dextra will attend The Bioprocessing Summit, on…
RSC LOGO CORPORATE A4 WEB
Apr 09, 2015

RSC Nucleosides and Nucleotides

We will be attending the RSC Nucleosides and Nucleotides meeting at Burlington House in…
BF61
Feb 20, 2015

L-Fucose

We are currently offering bulk quantities of L-fucose, with fast leadtimes and…
Informex
Jan 23, 2015

Dextra will be at InformEx

Dextra and New Zealand Pharmaceuticals Ltd will be attending InformEx in New Orleans, USA…
NU110 sm
Jan 13, 2015

New Products

Nucleotide Diphosphate Sugars We are now offering a range of nucleotide diphosphate…
Adhoc Logo
Nov 28, 2014

Distribution in China

Dextra are pleased to announce the appointment of Adhoc International as the exclusive…

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site

EU Cookie Directive Information